Return to content in this issue
Life-threatening idiopathic nonhistaminergic acquired angioedema with response to lanadelumab
Gamboa P, Galán C, Arrien A, Segurola A, Jáuregui I
Allergy Service, Hospital Universitario de Cruces, Barakaldo, Spain
J Investig Allergol Clin Immunol 2024; Vol. 34(1)
doi: 10.18176/jiaci.0926
Key words: Idiopathic bradykinergic angioedema, Landelumab, C1 inhibidor